SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001664710-24-000006
Filing Date
2024-01-04
Accepted
2024-01-04 16:04:12
Documents
15
Period of Report
2024-01-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kros-20240103.htm   iXBRL 8-K 42433
2 EX-1.1 exhibit11-8xk2024pricing.htm EX-1.1 350086
3 EX-5.1 exhibit51january2024.htm EX-5.1 11160
7 cooleylogo.jpg GRAPHIC 102892
  Complete submission text file 0001664710-24-000006.txt   750446

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20240103.xsd EX-101.SCH 1901
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20240103_lab.xml EX-101.LAB 25850
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20240103_pre.xml EX-101.PRE 13581
9 EXTRACTED XBRL INSTANCE DOCUMENT kros-20240103_htm.xml XML 2823
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 811173868 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39264 | Film No.: 24511773
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)